Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?

Leukemia Research

Volumn 36, Issue 7, 2012, Pages 832-840

  Cherry, Athena M ^a   Slovak, Marilyn L ^b   Campbell, Lynda J ^c   Chun, Kathy ^d   Eclache, Virginie ^e   Haase, Detlef ^f   Haferlach, Claudia ^g   Hildebrandt, Barbara ^h   Iqbal, Anwar M ⁱ   Jhanwar, Suresh C ^j   Ohyashiki, Kazuma ^k   Sole, Francesc ^l   Vandenberghe, Peter ^m   VanDyke, Daniel L ⁿ   Zhang, Yanming ^o   Dewald, Gordon W ⁿ  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^c ST VINCENT S HOSPITAL   (Australia)

^d NORTH YORK GENERAL HOSPITAL   (Canada)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

^g MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k TOKYO MEDICAL UNIVERSITY   (Japan)

^l HOSPITAL DEL MAR   (Spain)

^m UNIVERSITY OF LEUVEN   (Belgium)

ⁿ MAYO CLINIC   (United States)

^o University of Chicago   (United States)

more..

Author keywords

Bone marrow; Chromosome analysis; FISH; Fluorescence in situ hybridization; MDS; Myelodysplastic syndrome; Peripheral blood

Indexed keywords

5Q- SYNDROME; ADOLESCENT; ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BLOOD SAMPLING; BONE MARROW EXAMINATION; CHILD; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLONE SIZE; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MOLECULAR PROBE; MYELODYSPLASTIC SYNDROME; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BONE MARROW EXAMINATION; CHILD; CYTOGENETIC ANALYSIS; CYTOGENETICS; FEMALE; HEMATOLOGIC TESTS; HUMANS; KARYOTYPING; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MODELS, BIOLOGICAL; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; YOUNG ADULT;

EID: 84862339255     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.03.013     Document Type: Article

References (24)

1. Vardiman J.W., Harris N.L., Brunning R.D. The world health organization (WHO) classification of the myeloid neoplasma. Blood 2002, 100:2292-2302.
2. Jaffe E.S., Harris N.L., Stein H., Vardiman J. World Health Organization of Tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues 2001, International Agency for Research on Cancer, Lyon, France.
3. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q deletion. N Eng J Med 2006, 355:1456-1465.
4. Knapp R.H., Dewald G.W., Pierre R.V. Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 1985, 60:507-516.
5. Greenberg P., Anderson J., de Witte T., Estey E., Fenaux P., Gupta P., et al. Problematic WHO reclassification of myelodysplastic syndromes. J Clin Oncol 2000, 18:3447-3452.
6. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
7. Ketterling R.P., Wyatt W.A., VanWier S.A., Law M., Hodnefield J.M., Hanson C.A., et al. Primary myelodysplastic syndrome with normal cytogenetics Utility of 'FISH panel testing' and M-FISH. Leuk Res 2002, 26:235-240.
8. Cherry A.M., Brockman S.R., Paternoster S.F., Hicks G.A., Neuberg D., Higgins R.R., et al. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome An Eastern Cooperative Oncology Group (ECOG) study. Leuk Res 2003, 27:1085-1090.
9. Zou Y.S., Fink S.R., Stockero K.J., Paternoster S.F., Smoley S.A., Tun H.W., et al. Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with lenolidomide. Leuk Res 2007, 31:1185-1189.
10. Li X., Wu L., Ying S., Chang C., He Q., Pu Q. Differentiation and hematopoietic-support of clonal cells in myelodysplastic syndromes. Leuk Lymphoma 2007, 48:1353-1371.
11. Braulke F., Schanz J., Jung K., Shirneshan K., Schulte K., Schuetze C., et al. FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS. Verification of the method and application to 27 MDS patients. Leuk Res 2010, 34:1296-1301.
12. Coleman J.F., Theil K.S., Tubbs R.R., Cook J.R. Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute leukemia. A prospective analysis of 433 cases. Am J Clin Path 2011, 135:915-920.
13. Jakovleva K., Ogard I., Arvidsson I., Jacobsson B., Swolin B., Hast R. Masked monosomy 7 in myelodysplastic syndromes is uncommon and of undetermined clinical significance. Leuk Res 2001, 25:197-203.
14. Rigolin G.M., Bigoni R., Milani R., Cavazzini F., Roberti M.G., Bardi A., et al. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia 2001, 15:1841-1847.
15. Romeo M., Chauffaille MdL, Silva M.R.R., Bahia D.M.M., Kerbauy J. Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. Leuk Res 2002, 26:993-996.
16. Trost D., Hildebrandt B., Muller N., Germing U., Royer-Pokora B. Hidden chromosomal aberrations are rare in primary myelodysplastic syndromes with evolution to acute myeloid leukemia and normal cytogenetics. Leuk Res 2004, 28:171-177.
17. Costa D., Valera S., Carrio A., Arias A., Munoz C., Rozman M., et al. Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?. Leuk Res 2010, 34:1437-1441.
18. Pitchford C.W., Hettinga A.C., Reichard K.K. Fluorescence in situ hybridization testing for -5/5q-, -7/7q-, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study. Am J Clin Pathol 2010, 133:260-264.
19. Yang W., Stotler B., Sevilla D.W., Emmons F.N., Murty V.V., Alobeid B., et al. FISH analysis in addition to G-band karyotyping. Utility in evaluation of myelodysplastic syndromes?. Leuk Res 2010, 24:420-425.
20. Paulsson K., Heidenblad M., Strombeck B., Staaf J., Jonsson G., Borg A., et al. High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. Leukemia 2006, 20:840-846.
21. Suela J., Alvarez S., Cigudosa J.C. DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes. Cytogenet Genome Res 2007, 118:304-309.
22. Starczynowski D.T., Vercauteren S., Telenius A., Sung S., Tohyama K., Brooks-Wilson A., et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 2008, 112:3412-3424.
23. Slovak M.L., Smith D.D., Bedell V., Hsu Y.-H., O'Donnell M., Forman S.J., et al. Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes. Mol Cytogenet 2010, 3:23.
24. Thiel A., Beier M., Ingenhag D., Servan K., Hein M., Moeller V., et al. Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance. Leukemia 2011, 1-13.